Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) related to the company's US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), an increase in the notional allocation of Ordinary share ADRs occurred on January 20, 2012. The transaction price was $44.86 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items beyond the specific transaction notification. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: January 20, 2012 (Notification date: January 23, 2012).
- Transaction Price: $44.86 per ADR.
- Participants:
- Dr M M Slaoui (Director): 19 ADRs
- Dr K Slaoui (Connected Person): 5 ADRs
- Mr W C Louv (Director): 8 ADRs
- Dr D Pulman (Director): 13 ADRs
- Nature of Event: Increase in notional allocation within the US Retirement Savings Plan due to re-valuation.